Xue Siliang, Gu Rui, Wu Taixiang, Zhang Mingming, Wang Xiaoshan
Clinical Dermatology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, SiChuan, China, 610041.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD006136. doi: 10.1002/14651858.CD006136.pub2.
Sporotrichosis is a subacute or chronic disease, usually affecting the skin caused by a dimorphic (existing in two forms), aerobic (oxygen requiring) fungus called Sporothrix schenckii. Oral potassium iodide is widely used for cutaneous sporotrichosis in clinical medicine with more and more reports published. However, the benefits and adverse reactions of these treatments have not yet been systematically reviewed.
To assess the effects of oral potassium iodide for the treatment of sporotrichosis.
In July 2009 we searched the Cochrane Skin Group Specialised Skin Register, the Cochrane Central Register of Controlled Clinical Trials (CENTRAL) in The Cochrane Library (Issue 3, 2009), MEDLINE and EMBASE, The Chinese Biomedical Database, CNKI, VIP, and ongoing trials registers.
Randomised trials comparing orally administered iodide with placebo, or with another treatment. Studies about potassium iodide as an adjunct were excluded.
Two authors planned to independently assess trial quality and extract data. We also planned to collect adverse effects information from the trials where possible.
In the absence of any suitable randomised placebo-controlled trials or comparisons with other treatments in this area, we were unable to assess the effects of oral potassium iodide.
AUTHORS' CONCLUSIONS: The currently available evidence is insufficient to assess the potential for oral potassium iodide in the treatment of sporotrichosis.There is no high-quality evidence for or against oral potassium iodide as a treatment for sporotrichosis. Further randomised double-blind placebo-controlled trials are needed to define the efficacy and acceptability of these interventions.
孢子丝菌病是一种亚急性或慢性疾病，通常由一种二态性（以两种形式存在）、需氧（需要氧气）的真菌申克孢子丝菌引起，主要影响皮肤。口服碘化钾在临床医学中被广泛用于皮肤孢子丝菌病，且相关报道越来越多。然而，这些治疗方法的益处和不良反应尚未得到系统评价。
评估口服碘化钾治疗孢子丝菌病的效果。
2009年7月，我们检索了Cochrane皮肤组专业皮肤登记册、Cochrane图书馆（2009年第3期）中的Cochrane临床对照试验中心注册库（CENTRAL）、MEDLINE和EMBASE、中国生物医学数据库、中国知网、维普资讯以及正在进行的试验注册库。
比较口服碘化物与安慰剂或其他治疗方法的随机试验。排除关于碘化钾作为辅助治疗的研究。
两位作者计划独立评估试验质量并提取数据。我们还计划尽可能从试验中收集不良反应信息。
由于该领域缺乏合适的随机安慰剂对照试验或与其他治疗方法的比较研究，我们无法评估口服碘化钾的效果。
现有证据不足以评估口服碘化钾治疗孢子丝菌病的潜力。目前尚无高质量证据支持或反对口服碘化钾治疗孢子丝菌病。需要进一步开展随机双盲安慰剂对照试验来确定这些干预措施的疗效和可接受性。
